Giusy Ferraro

Dr. Giusy Ferraro

University of Salerno, Fisciano, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GFGiusy Ferraro
Giusy Ferraro
MMMatteo Mozzicafreddo
Matteo Mozzicafreddo
Roberta EttariRoberta Ettari
Roberta Ettari
Lorenzo CorsiLorenzo Corsi
Lorenzo Corsi
Maria Chiara MontiMaria Chiara Monti
Maria Chiara Monti
In the last few years, several efforts have been made to identify original strategies against glioblastoma multiforme (GBM): this requires a more detailed investigation of the molecular mechanism of GBM so that novel targets can be identified for new possible therapeutic agents. Here, using a combined biochemical and proteomic approach, we evaluated the ability of a blood–brain barrier-permeable 2,3-benzodiazepin-4-one, called 1g, to interfere with the activity and the expression of brain glycogen phosphorylase (PYGB) on U87MG cell line in parallel with the capability of this compound to inhibit the cell growth and cycle. Thus, our results highlighted PYGB as a potential therapeutic target in GBM prompting 1g as a capable anticancer drug thanks to its ability to negatively modulate the uptake and metabolism of glucose, the so-called “Warburg effect”, whose increase is considered a common feature of cancer cells in respect of their normal counterparts.

Verified
Journal Article
Open access
PDF file
MTMichela Terlizzi
Michela Terlizzi
CCChiara Colarusso
Chiara Colarusso
GFGiusy Ferraro
Giusy Ferraro
AFAnna Falanga
Anna Falanga
Maria Chiara MontiMaria Chiara Monti
Maria Chiara Monti
RAFFAELLA SORRENTINORAFFAELLA SORRENTINO
RAFFAELLA SORRENTINO
Sex is a biological variable that can reflect clinical outcomes in terms of quality of life, therapy effectiveness, responsiveness and/or toxicity. Sphingosine-1-phosphate (S1P) is a lipidic mediator whose activity can be influenced by sex. To evaluate whether the S1P axis underlies sex ‘instructions’ in the lung during physiological and oncological lung conditions, sphingosine and S1P were quantified in the blood of healthy (H) volunteers, lung adenocarcinoma (ADK) and squamous cell carcinoma (SCC) patients of both sexes. S1P receptors and their metabolic enzymes were evaluated in the tissues. Circulating levels of S1P were similar among H female and male subjects and female SCC patients. Instead, male and female ADK patients had lower circulating S1P levels. S1P receptor 3 (S1PR3) was physiologically expressed in the lung, but it was overexpressed in male SCC, and female and male ADK, but not in female SCC patients, who showed a significantly reduced ceramide synthase 1 (CERS1) mRNA and an overexpression of the ceramidase (ASAH1) precursor in lung tumor tissues, compared to male SCC and both male and female ADK patients. These findings highlighted sex differences in S1P rheostat in pathological conditions, but not in physiological conditions, identifying S1P as a prognostic mediator depending on lung cancer histotype.

26 April 2023 in Population Medicine
Verified
Journal Article
Open access
GRGiuseppina La Rosa
Giuseppina La Rosa
DBDavid Brandtner
David Brandtner
GFGiusy Ferraro
Giusy Ferraro
Elisabetta SuffrediniElisabetta Suffredini
Elisabetta Suffredini
CVCarolina Veneri
Carolina Veneri
LLLuca Lucentini
Luca Lucentini
Background and objective: Three SARS-CoV-2 Variants of Concern (VoCs) are circulating in the European Union/European Economic Area (EU/EEA) countries as of December 2022: Omicron BA.2, BA.4, and BA.5. ECDC also currently recognizes three Variants of Interest (VOIs): Omicron BA.2.75, BQ.1, and...

1 May 2023
Verified
Conference Paper
Closed access
EGElisabetta Granato
Elisabetta Granato
ICIda Cerqua
Ida Cerqua
MRM.A. Riemma
M.A. Riemma
ARAdriana Rossi
Adriana Rossi
MNM.F. Nani
M.F. Nani
FRFiorentina Roviezzo
Fiorentina Roviezzo